A team of researchers designed a study to find out if there was a difference between two treatments for heart disease and the outcomes it produces.
A drug eluting stent, a coronary stent placed into narrowed arteries that slowly released drugs, was compared with a bare metal stent (does not carry the drug) with an externally administered drug, thienopyridine.
A set of treatments was compared to find the rate of thrombosis, adverse cardiac events or bleeding in patients. Bare metal stent (BMS) placement following elective percutaneous coronary intervention (PCI) such as stent placement and 1 month of DAPT was compared with 6 to 12 months for drug-eluting stents (DES).
Moderate or severe bleeding was less in the placebo but the rate of thrombosis and major cardiac events in the patients who continued thienopyridine was less than the placebo. Similarly, thrombosis rate and major cardiac events were fewer in BMS than DES while bleeding was more in BMS. The results comparing continued thienopyridine vs placebo in the cohort treated with DES demonstrated significant reductions in stent thrombosis and major cardiac events.